Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method
Open Access
- 28 October 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 585768
Abstract
Human papillomavirus (HPV) vaccines are safe and effective in preventing HPV infection and cervical precancers. Neutralising antibodies are thought to be the primary mechanism of protection for HPV vaccines, although the exact level required for protection has not been identified. Three common serological assays used in clinical trials to measure HPV antibodies are HPV pseudovirion-based neutralisation assay (PBNA), competitive or total Luminex immunoassays (cLIA or LIA) and VLP-based enzyme linked immunosorbent assays (ELISA). While PBNA is the gold-standard for measuring neutralising antibodies (NAb), it is labour intensive. Luminex immunoassay and VLP-ELISA are rapid and high throughput, but their reagents and equipment can be difficult to source. Nevertheless, data generated from these assays generally correlate well with PBNA. Here, we described a simplified high-throughput PsV-based ELISA for HPV antibody measurement, to circumvent some of the limitations of existing assays. Using this assay, we were able to differentiate HPV-specific IgG and IgM, and found a strong correlation between HPV-specific IgG and NAb levels, as previously determined by PBNA. This assay platform is simpler and less time-consuming than PBNA. In addition, the materials can be readily produced and obtained commercially. This assay can be used as an alternative method to measure HPV antibodies.Keywords
Funding Information
- Department of Foreign Affairs and Trade, Australian Government
This publication has 12 references indexed in Scilit:
- Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirusInfection and Drug Resistance, 2019
- Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian studyVaccine, 2018
- Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and developmentVaccine, 2018
- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studiesVaccine, 2018
- Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort StudyClinical Infectious Diseases, 2016
- Human papillomavirus vaccines: WHO position paper, October 2014.2014
- Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesHuman Vaccines & Immunotherapeutics, 2014
- Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three AssaysFrontiers in Oncology, 2014
- The first international standard for antibodies to HPV 16Vaccine, 2011
- Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays2005